Mijn Ikazia
Spoed
Patientinformatie
Praktische informatie
Contact
Onderzoek in Ikazia - Interne geneeskunde - Drooger
Publicaties internist-oncoloog dhr. dr. J.C. Drooger
- Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
NPJ Breast Cancer. 2023 Jul 14;9(1):61. doi: 10.1038/s41523-023-00563-w. - The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
ESMO Open. 2023 Feb;8(1):100786. doi: 10.1016/j.esmoop.2023.100786. - Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
JAMA Netw Open. 2022 Nov 1;5(11):e2244350. doi: 10.1001/jamanetworkopen.2022.44350. - The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
Int J Cancer. 2022 Aug 15;151(4):616-622. doi: 10.1002/ijc.34024 - Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
Eur J Cancer. 2022 Jan:160:261-272. doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25. - Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
Breast Cancer Res Treat. 2021 Apr;186(3):851-862. doi: 10.1007/s10549-020-06039-w - Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
Eur J Cancer. 2020 Dec:141:171-184. doi: 10.1016/j.ejca.2020.09.027 - Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
Breast Cancer Res Treat. 2019 Dec;178(3):597-605 - First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
Oncologist. 2017 Aug;22(8):901-909. doi: 10.1634/theoncologist.2016-0448 - Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
Med Oncol. 2015 Apr;32(4):113. doi: 10.1007/s12032-015-0550-x - ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics
-een van de auteurs: internist-oncoloog dhr. J.C. Drooger
Open Rheumatol J. 2009 Mar 4:3:14-7. doi: 10.2174/1874312900903010014
Twitter
Facebook
Linkedin
E-mail
Whatsapp